PT  - JOURNAL ARTICLE
AU  - Yira Feshchenko
AU  - Ludmila Iashyna
AU  - Maryna Polianska
AU  - Inna Zvol
AU  - Alyona Potocjniak
AU  - Ludmila Savelieva
TI  - Clinical effectiveness of antidepressive drug in patients with COPD and concomitant moderate depressive episode
DP  - 2013 Sep 01
TA  - European Respiratory Journal
PG  - P3653
VI  - 42
IP  - Suppl 57
4099  - http://erj.ersjournals.com/content/42/Suppl_57/P3653.short
4100  - http://erj.ersjournals.com/content/42/Suppl_57/P3653.full
SO  - Eur Respir J2013 Sep 01; 42
AB  - Aim of study: to study the effectiveness of agomelatin on clinical symptoms in COPD patients with moderate depressive episode (DE). Study was carried out because of budjet cost.Materials and methods: 19 COPD (post BD FEV1/FVC<0,7) patients with moderate DE (PHQ-9 score > 15), 7 female and 12 male, mean age (61,7 ± 2,6) years received agomelatin 25 mg 1 hour before sleep OD during 4 weeks on the background of standard COPD therapy according severity. Depressive episode was verified by psychiatrist. Patients were assessed with questionnaires PHQ-9, MADRS, mMRC, CAT score, EQ-5D, also were performed 6-min walk test with BORG scale (physical tolerability) in baseline, in 2 and 4 weeks.Results: Signs of depression significantly (p<0,05) improved after 2 weeks of studied treatment with further positive dynamics on 4 week : PHQ-9 improved from (16,4 ±0,4) to (12,5 ±1,1) after 2 weeks and to (10,4±1,1) to 4 week, MADRS – from (25,0±1,2) to (19,1±1,4) and to (17,3±1,4) accordingly. Positive psychiatry changes were accompanied with improvement of clinical signs of COPD: significantly (p<0,05) decreased at the end of 4 week vs baseline data: dyspnea (mMRC) from (2,4 ±0,2) to (2,1±0,1), CAT test – from (20,9±1,6) to (17,9±1,5), EQ-5D from (9,1 ±1,6) to (7,9±0,5). Physical tolerability improved – walking distance increased from (258,7±11,3) m to (277,4 ±12,2) m (p<0,05).Conclusion: use of agomelatin in complex COPD therapy in patients with COPD and moderate depressive episode caused decrease of depressive signs after 2 weeks of therapy with further improvement to 4 week. Clinical signs of COPD, including tolerability of physical load also improved (p<0,05).